Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.

After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon ...

Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

CLEVELAND, Ohio— The Cleveland biotech start-up Asclepii, founded in a college dorm room, is seeking to change lives for ...

A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

Angel investors are raising the bar with tighter criteria, backing strong teams, realistic markets and clear paths to exit ...

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...